psoriasis

Armstrong AW, Jaleel T, Merola JF, Gottlieb AB, Khattri S, Helt CC, Malatestinic WN, Ross SE, Ngantcha ME, de Vlam K. Ixekizumab Demonstrates Rapid and[...]

Lebwohl MG, Koo JY, Armstrong AW, Strober BE, Martin GM, Rawnsley NN, Goehring EL Jr, Jacobson AA. Brodalumab: 5-Year US Pharmacovigilance Report. Dermatol Ther (Heidelb).[...]

Egeberg A, Hawkes JE, Somani N, Burge R, See K, Gallo G, McKean-Matthews M, Gooderham M, Han G, Armstrong A. Sustained Improvements in Clinical and[...]

Lebwohl M, Merola JF, Strober B, Armstrong A, Yoshizaki A, Gisondi P, Szilagyi B, Peterson L, de Cuyper D, Cross N, Davies O, Gottlieb AB.[...]

Peterson H, Huang MY, Lee K, Kingston P, Yee D, Korouri E, Agüero R, Armstrong AW. Comorbidity Burden in Psoriasis Patients with Skin of Color.[...]

Vaccination Recommendations for Adults Receiving Biologics and Oral Therapies for Psoriasis and Psoriatic Arthritis: Delphi Consensus from the Medical Board of the National Psoriasis Foundation[...]

Armstrong AW, Jayade S, Rege S, Joshi N, Patel V, Kalirai S, Wolin D, Boyle K, Patel D, Seigel L. Evaluating Treatment Choice in Patients[...]

Kingston P, Blauvelt A, Strober B, Armstrong AW. Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis. J Psoriasis Psoriatic Arthritis. 2023 Oct;8(4):156-165.[...]

Song WB, Garshick MS, Barbieri JS, Shin DB, Báez S, Papadopoulos M, Neopaney A, Fitzsimmons R, Kalb RE, Mease PJ, Craig ET, Koplin J, Takeshita[...]

Blauvelt A, Rich P, Sofen H, Strober B, Merola JF, Lebwohl M, Morita A, Szepietowski JC, Lambert J, Hippeli L, Colston E, Balagula E, Banerjee[...]